Drug Name |
Terazosin |
Drug ID |
BADD_D02158 |
Description |
Terazosin is a quinazoline derivative alpha-1-selective adrenergic blocking agent indicated for benign prostatic hyperplasia and hypertension[FDA Label][A176831]. Terazosin blocks adrenaline's action on alpha-1 adrenergic receptors, causing relaxation of smooth muscle in blood vessels and the prostate[A176837]. |
Indications and Usage |
For the treatment of symptomatic BPH and mild to moderate hypertension. |
Marketing Status |
Prescription; Discontinued |
ATC Code |
G04CA03 |
DrugBank ID |
DB01162
|
KEGG ID |
D08569
|
MeSH ID |
C041226
|
PubChem ID |
5401
|
TTD Drug ID |
D0P9RF
|
NDC Product Code |
70518-3193; 23155-738; 70518-3272; 23155-737; 67296-1264; 70518-3211; 23155-735; 23155-736 |
Synonyms |
Terazosin | Adecur | Apo-Terazosin | Dysalfa | Hytrin | Flotrin | Hytrin BPH | Hytrine | Heitrin | Deflox | Magnurol | Novo-Terazosin | Nu-Terazosin | PMS-Terazosin | terazosin hydrochloride anhydrous | Sutif | Tazusin | Terazoflo | Terazosin AZU | Terazosin Hexal | Terazosin hydrochloride | terazosin, monohydrochloride, dihydrate | Terazosina Alter | Terazosina Kern | Terazosina Qualix | Zayasel | A 45975 | ratio-Terazosin |